Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Directors Deals Ltd.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Hikma Pharmaceuticals Plc Raises FY 2013 Revenue Guidance


Monday, 8 Jul 2013 02:00am EDT 

Hikma Pharmaceuticals Plc announced that it expects group revenue to grow by around 17%, up from the previous guidance of around 13%. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.256 billion for fiscal 2013. 

Company Quote

2010.0
-39.0 -1.94%
10:07am EST